TRINETRA › Sectors › Healthcare
Dishman Carbogen Amcis Limited (DCAL) — share price, P/E and fundamentals
Dishman Carbogen Amcis Limited (NSE: DCAL) closed at ₹145.02 on 30 Oct 2026, -47.9% over one year, against a 52-week range of ₹128.50 – ₹303.00.
In the quarter ended 30 Jun 2026 (consolidated, filed 14 Aug 2026) it reported revenue of ₹678 cr and a net loss of ₹58 cr, a -8.5% net margin; revenue fell 4.3% year on year.
On four consecutive filed quarters its trailing P/E is 140.7; since 21 May 2025 its own P/E has ranged from 17.2 to 1,497.1 (median 176.5), and today's reading is higher than 38% of those 357 trading days.
From the balance sheet dated 31 Mar 2026: return on equity -3.5%, ROCE -0.6%, debt-to-equity 0.42, Piotroski F-score 7 of 9.
Against 66 Healthcare peers on NSE: Net margin higher than 2% of 64 sector peers; PBT margin higher than 3% of 64 sector peers; ROE higher than 3% of 64 sector peers.
Key figures
| Last close | ₹145.02 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -13.8% / -14.2% / -47.9% |
| 52-week low – high | ₹128.50 – ₹303.00 |
| Market capitalisation | ₹2,274 cr |
| Trailing P/E | 140.7 |
| Price / book | 0.34 |
| EV / EBITDA | 8.0 |
| Earnings yield | 0.7% |
| TTM EPS | ₹1.03 |
| TTM net profit | ₹16 cr |
| Quarter revenue | ₹678 cr |
| Quarter net loss | ₹58 cr |
| Net margin | -8.5% |
| Revenue growth (YoY) | -4.3% |
| Return on equity | -3.5% |
| ROCE | -0.6% |
| Debt / equity | 0.42 |
| Current ratio | 1.23 |
| Free cash flow | ₹225 cr |
| Piotroski F-score | 7 / 9 |
| Average daily turnover (50 days) | ₹2.6 cr |
Against Healthcare peers
| Metric | DCAL | Peer median | Percentile |
|---|---|---|---|
| Net margin | -8.54 | 12.89 | 2 |
| PBT margin | -7.56 | 17.68 | 3 |
| ROE | -3.47 | 13.87 | 3 |
| ROCE | -0.59 | 17.26 | 5 |
| Debt / equity | 0.42 | 0.11 | 81 |
| Cash conversion | 5.04 | 1.25 | 97 |
| Trailing P/E | 140.71 | 43.26 | 95 |
| P/B | 0.34 | 6.02 | 0 |
Questions
What is the P/E ratio of Dishman Carbogen Amcis Limited?
Dishman Carbogen Amcis Limited's trailing P/E is 140.7, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 21 May 2025 its P/E has ranged 17.2–1,497.1.
What were Dishman Carbogen Amcis Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Dishman Carbogen Amcis Limited reported revenue of ₹678 cr and a net loss of ₹58 cr (consolidated), filed with the exchange on 14 Aug 2026.
What is Dishman Carbogen Amcis Limited's ROE?
Return on equity is -3.5% based on the balance sheet dated 31 Mar 2026.
Does Dishman Carbogen Amcis Limited have debt?
Debt-to-equity is 0.42 on the balance sheet dated 31 Mar 2026.
What is DCAL's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, DCAL traded between ₹128.50 and ₹303.00.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.